Abstract: Disclosed is an image analysis method including inputting analysis data, including information regarding an analysis target cell to a deep learning algorithm having a neural network structure, and analyzing an image by calculating, by use of the deep learning algorithm, a probability that the analysis target cell belongs to each of morphology classifications of a plurality of cells belonging to a predetermined cell group.

Abstract: An immunity inducer contains, as an active ingredient, any of a peptide (a) or (b) below, or an expression vector having a structural gene including a region encoding the peptide. (a) A peptide including an amino acid sequence represented by SEQ ID NO: 1 or 2; (b) a peptide having immunity induction activity and including an amino acid sequence in which one or several amino acids are deleted, substituted or added in the amino acid sequence represented by SEQ ID NO: 1 or 2. A pharmaceutical composition for preventing or treating aging-related diseases includes the immunity inducer and an adjuvant.

Abstract: A method for producing pancreatic endocrine cells, including introducing (A), (B), (C), or (D) is provided. The pancreatic endocrine cells are produced without undergoing an iPS cell stage. The mutated GLIS1 gene having a sequence identity of 85% or more to a base sequence as set forth in SEQ ID NO: 1 or one or more gene products thereof in (A), (B), or (D) is a mutated GLIS1 gene having at least one of (i) addition of any base(s) to 5?-terminus of the mutated GLIS1 gene having sequence identity of 85% or more to the base sequence as set forth in SEQ ID NO: 1 and (ii) addition of any base(s) to 3?-terminus of the mutated GLIS1 gene having sequence identity of 85% or more to the base sequence as set forth in SEQ ID NO: 1.

Abstract: An AMD risk evaluation method is provided. The concentrations of a set of evaluation elements contained in a serum sample 2 taken from a subject are measured (step S1), the concentration data of the set of evaluation elements thus measured are applied to a predetermined discriminant function to perform an operation (step S2); and whether or not the subject suffers from AMD is discriminated based on the operation result obtained by applying the concentration data to the discriminant function (step S3). The discrimination is carried out in accordance with the concentration balance (pattern) of the set of evaluation elements. The set of evaluation elements is designated by choosing all or part of specific elements that have the concentration data for both of the case group and the control group based on the discriminant abilities in arbitrary combinations of the specific elements.

Abstract: A method for producing pancreatic endocrine cells, the method including introducing one or more genes of a GLIS family or one or more gene products thereof and a Neurogenin3 gene or one or more gene products thereof into somatic cells.

Abstract: A method for producing pancreatic endocrine cells, the method including introducing one or more genes of a GLIS family or one or more gene products thereof and a Neurogenin3 gene or one or more gene products thereof into somatic cells.

Abstract: [Problem] The present invention addresses the problem of providing an anti-Staphylococcus antibody having preventive or therapeutic effects on staphylococcal infections. [Solution] Provided is an anti-Staphylococcus antibody having preventive or therapeutic effects on staphylococcal infections and a method for manufacturing said antibody, as well as a composition, a product, and a drug containing said antibody. The antibody is obtained by using deacetylated Staphylococcus for immunization.

Abstract: Provided is a test method for the assessment of the necessity of renal biopsy in a subject to be tested, who is suspected of having a renal disease. Specifically provided are a test method for a renal disease, including using urinary podocalyxin and one or more additional markers in combination, and a test reagent for use in the test method and a test reagent kit for use in the test method. The present invention allows the discrimination of a poor prognosis group even for poor prognosis cases with no overt findings in a conventional test method, and thus allows the assessment of a renal disease, the assessment of the necessity of renal biopsy, prognostic prediction, and the like to be performed exactly.

Abstract: Provided is a test method for the detection of diabetic nephropathy at an early stage as compared to a conventional method. Specifically provided are: a test method for diabetic nephropathy, including detecting urinary podocalyxin; the test method, further including assessing diabetic nephropathy at at least Stage I; a test reagent for use in the test method; and a test reagent kit for use in the test method. The present invention is based on a finding that urinary podocalyxin reflects the development and condition of diabetic nephropathy with high sensitivity at an early stage as compared to urinary albumin.

Abstract: [Problem] The present invention addresses the problem of providing an anti-Staphylococcus antibody having preventive or therapeutic effects on staphylococcal infections. [Solution] Provided is an anti-Staphylococcus antibody having preventive or therapeutic effects on staphylococcal infections and a method for manufacturing said antibody, as well as a composition, a product, and a drug containing said antibody. The antibody is obtained by using deacetylated Staphylococcus for immunization.

Abstract: This invention provides a diagnostic kit and a diagnostic marker used for diagnosing a renal disease. This invention also provides a method for detecting a renal disease comprising measuring at least one type of human megalin existing in urine selected from among full-length human megalin and human megalin fragments of (i) to (iii): (i) full-length human megalin; (ii) a human megalin endodomain fragment lacking a human megalin ectodomain; and (iii) a human megalin ectodomain fragment lacking a human megalin endodomain.

Abstract: This invention provides a simple means for detecting a renal disorder, a diagnostic marker for a renal disorder that enables prognostic prediction of a renal disorder (e.g., diabetic nephropathy and IgA nephropathy) and evaluation of the degree of nephropathy at the phase of stage-II diabetic nephropathy by measuring the megalin level in urine associated with a renal disorder used for the detection means, and use of such marker. The invention also provides the use of human megalin obtained from the urine sample of a subject as a marker for detecting a renal disorder.

Abstract: A therapeutic agent for treatment of herpes virus-derived pain which comprises (±)-[2-[4-(3-ethoxy-2-hydroxy-propoxy) phenylcarbamoyl]ethyl]dimethylsulfonium p-toluenesulfonate represented by the formula (1) as an active ingredient.

Abstract: The present invention is directed to a pharmaceutical composition for the treatment of steroid depending and/or steroid resistive ulcerative colitis. The pharmaceutical composition, which is administered to treat steroid depending and/or steroid resistive ulcerative colitis, contains, as the active ingredients, at least one compound selected from a group consisting of tetracyclines, penicillins, and nitroimidazoles.